Company: Regeneron

Clinical trial(s): NIMBLE (estimated to complete 23/3/28) link to trial  Recruiting in UK sites: Birmingham and Sheffield

NICE status: No appraisal status at present time

MHRA status: Not approved at present time

·        Pozelimab and Cendisiran are both complement inhibitors and work similarly to zilucoplan, eculizumab, and ravulizumab. There are being used as a combinatorial therapy to treat myasthenia gravis.